Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Authors:
Open Access
- 1 May 2009
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 20 (suppl_4) , iv108-iv109
Abstract
The crude incidence of Hodgkin lymphoma (HL) in the European Union is 2.2, the mortality is 0.7/100 000 cases/year.Keywords
This publication has 10 references indexed in Scilit:
- FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphomaCurrent Opinion in Oncology, 2008
- Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationJournal of Clinical Oncology, 2008
- Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Blood, 2008
- Autologous and Allogeneic Stem Cell Transplantation in Hodgkin's LymphomaHematology/Oncology Clinics of North America, 2007
- Relapsed and Refractory Hodgkin Lymphoma: Transplantation Strategies and Novel Therapeutic OptionsCurrent Treatment Options in Oncology, 2007
- Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphomaHaematologica, 2007
- Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcomeBlood, 2006
- Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 2003
- Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trialThe Lancet, 2002
- Long-Term Follow-up of Hodgkin's Disease TrialNew England Journal of Medicine, 2002